Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis
Author Department
Medicine
Document Type
Article, Peer-reviewed
Publication Date
5-1-2011
Abstract
The human innate immune system initiates inflammation in response to bacterial molecules, particularly Gram-negative bacterial endotoxin. The steps by which endotoxin exposure leads to systemic inflammation include binding to Toll-like receptor-4 that specifically recognizes endotoxin and subsequently triggers cellular and molecular inflammatory responses. Severe sepsis is a systemic inflammatory response to infection that induces organ dysfunction and threatens a person's survival. Severe sepsis is frequently associated with increased blood levels of endotoxin. It is a significant medical problem that effects approximately 700,000 patients every year in the USA, resulting in 250,000 deaths. Eritoran tetrasodium is a nonpathogenic analog of bacterial endotoxin that antagonizes inflammatory signaling by the immune receptor Toll-like receptor-4. Eritoran is being evaluated for the treatment of patients with severe sepsis.
Publication ISSN
0004-0010
Recommended Citation
Tidswell M, Larosa S. Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis Expert Rev Anti Infect Ther 2011 May;9(5):507-20.